Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy

Immune checkpoint inhibition for the treatment of cancer has provided a breakthrough in oncology, and several new checkpoint inhibition pathways are currently being investigated regarding their potential to provide additional clinical benefit. However, only a fraction of patients respond to such tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Borch, Annie, Bjerregaard, Anne-Mette, Araujo Barbosa de Lima, Vinicius, Østrup, Olga, Yde, Christina Westmose, Eklund, Aron Charles, Mau-Sørensen, Morten, Barra, Carolina, Svane, Inge Marie, Nielsen, Finn Cilius, Funt, Samuel A., Lassen, Ulrik, Hadrup, Sine Reker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076713/
https://www.ncbi.nlm.nih.gov/pubmed/37035751
http://dx.doi.org/10.3389/fgene.2023.1058605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076713/
https://www.ncbi.nlm.nih.gov/pubmed/37035751
http://dx.doi.org/10.3389/fgene.2023.1058605

Ejemplares similares